Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06904625 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer

Study acronym: CAPT CTC
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 36 to 54
    • Primary and study completion dates: May 2026 to Nov 2026
    • Secondary endpoints: details revised at 2 of 2 entries
    v4
  2. Start date changed from estimate of Aug 2025 to Aug 14, 2025v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 2025 to Aug 2025
    • Primary and study completion dates: Jan 2026 to May 2026
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial is a pilot, prospective, single-center study conducted in a population of patients with metastatic breast cancer (whatever the immunohistochemical subtype) or metastatic prostate cancer. The aim of this exploratory study is to compare the sensitivity of three different techniques (CellSearch®, Parsortix® and SmartCatch®) in detecting circulating tumor cells (CTCs). After the patient's agreement, and before starting anti-tumor treatment, a blood sample will be taken using the 3 different CTC detection techniques. Each patient will participate in the study for one day. A total of 54 evaluable patients (36 patients with metastatic breast cancer and 18 patients with metastatic prostate cancer) will be included in this interventional study.
Trial Details
NCT Number NCT06904625
Lead Sponsor Institut Claudius Regaud
Conditions
(from sponsor)		 Metastatic Breast Cancer, Metastatic Prostate Cancer
Related terms Breast Neoplasms, Neoplastic Cells, Circulating, Prostatic Neoplasms
Enrollment 54 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov